|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
ABSTRACT |
|---|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Myocardial depression can be demonstrated following administration of endotoxin. Proposed mechanisms of endotoxin-induced myocardial dysfunction include the release of proinflammatory mediators, focal myocardial ischemia, and the presence of activated leukocytes within the myocardium. Recently, myocardial caspase activation and mitochondria-related apoptotic events (i.e., release of cytochrome c) were demonstrated in the failing septic heart. Here, we tested the hypothesis that immunosuppressors, cyclosporin A and tacrolimus (FK 506), would improve inflammation, heart nuclear apoptosis, and myocardial dysfunction in endotoxin-treated rats. Myocardial contractility was assessed using an isolated heart preparation. Heart leukocyte infiltration was assessed by measurement of heart myeloperoxidase activity. Leukocyte activation was studied using the intravital microscopy of the mesenteric venule. Apoptosis was detected as myocardial DNA fragmentation, downstream caspase activation, and mitochondrial cytochrome c release. Both cyclosporin A and FK 506 reduced heart leukocyte sequestration and venular adhesion in endotoxin-treated rats. Cyclosporin A, which blocks mitochondrial cytochrome c release, was able to reduce endotoxin-induced myocardial end-stage nuclear apoptosis and heart dysfunction, whereas tacrolimus had no such effects. These effects could be related to the unique properties of cyclosporin A to act on mitochondria.
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Keywords: endotoxin; cardiomyocyte; mitochondria; cytochrome c; apoptosis
Human and animal studies have shown that myocardial contractile depression is an early manifestation of sepsis syndrome (1). Myocardial depression can be demonstrated in experimental animal models following administration of endotoxin, a lipopolysaccharide component of the outer membrane of gram-negative
bacteria (2, 4, 5). Although the etiology of myocardial contractile
dysfunction in this condition is incompletely described, potential
mechanisms include the effects of circulating and locally produced "depressant substances" such as proinflammatory cytokines, for example, tumor necrosis factor (TNF)-
and nitric oxide (6), focal myocardial ischemia and necrosis (10), and the
presence of activated leukocytes within the myocardium (11, 12).
In the heart, apoptosis may be activated under conditions
such as cytokine stimulation. Indeed, proinflammatory cytokine
TNF- directly induces apoptosis of cardiomyocytes in vitro
(13). Furthermore, we and other groups have recently shown
that sepsis may also trigger apoptotic pathways in the heart and
that these events may contribute to endotoxin-induced myocardial dysfunction (14). In most cases, the execution phase of
the apoptotic process involves the participation of mitochondria
as caspase activators (17, 18). Mitochondria release cytochrome
c into the cytosol, where it binds to and induces oligomerization
of Apaf-1 (19, 20). Once activated by cytochrome c, oligomerized Apaf-1 then binds procaspase-9, resulting in procaspase-9
proteolytic self-processing and activation of caspase-3, which
participates as a terminal effector of apoptosis by cleaving crucial nuclear substrates (20). In sepsis, myocardial upstream and
downstream caspase activation, as well as mitochondria-related
apoptotic events such as release of cytochrome c, was recently
demonstrated in the failing septic heart (15, 16).
A large body of evidence suggests that inflammation and apoptosis pathway activation contribute to endotoxin-induced myocardial dysfunction. In this context, we hypothetized that immunosuppressive compounds, that is, cyclosporin A (CsA) and tacrolimus (FK 506), would alter heart inflammation and apoptosis and ameliorate myocardial dysfunction in sepsis. Indeed, CsA and FK 506 are calcineurin inhibitors believed to exert their action through binding to cyclophilins and FK binding proteins, also known as immunophilins (21). When complexed with CsA and FK 506, the properties of immunophilins change, leading to the inhibition of the phosphatase calcineurin and subsequent inhibition of T cell activation. In addition, calcineurin inhibitors have been shown to inhibit cell apoptosis in vitro through mechanisms compatible with inhibition of mitochondrial permeability transition related to the opening of a megachannel in the inner mitochondrial membrane, cytochrome c release, and increases in levels of proteins of the Blc-2 family (22, 23). In vivo, analogues of CsA that block the mitochondrial permeability transition in isolated mitochondria are able to reduce reperfusion-induced myocardial dysfunction (22, 24, 25). Although these findings suggest that under certain conditions, calcineurin inhibitors may improve the function of the reperfused myocardium, the effects of CsA and FK 506 on endotoxin-induced myocardial inflammation and apoptosis have not been specifically addressed in the septic heart.
Therefore, in this study, we examined the protective effects
of cyclosporin A and tacrolimus on myocardial dysfunction in heart from endotoxin-treated rats. The results of this study
provide new pieces of information: (1) both CsA and FK 506 were able to reduce heart leukocyte sequestration, vascular
leukocyte activation, and serum concentrations of TNF- and
(2) CsA, but not FK 506, was able to offer protection to endotoxin-induced myocardial cell apoptosis and improve myocardial function.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Animal Preparation
Care and use of animals were in accordance with our institution's guidelines for the care and use of laboratory animals. Six groups of adult male Sprague-Dawley rats were studied, that is, saline-treated (control animals), endotoxin-treated (Endo. 10 mg/kg of endotoxin from Escherichia coli serotype 055:B5), CsA-treated (10 mg/kg) and FK 506-treated (3 mg/kg) control and endotoxin-treated rats. Four hours after treatment, rats were prepared for either physiological measurements or for in vitro assays.
Physiological Measurements
Isolated and perfused heart preparationMyocardial contractile function was studied using a modified Langendorff isolated heart preparation as we have previously described (26).
Leukocyte adhesion in the mesenteric venulesThe mesenteric microcirculation was observed with the use of an intravital microscope (Eclipse E800 Nikon microscope, Tokyo, Japan). As previously described, single unbranched mesenteric venules were selected for study of leukocyte rolling and adhesion (27, 28).
Biochemical Measurements
Cytokine determination and leukocyte countSerum levels of interleukin (IL)-1
, IL-6, and TNF- were determined by use of commercially available immunoassay kits (enzyme-linked immunosorbent assay [ELISA]). Circulating blood leukocytes and differential counts of leukocytes were performed.
Myeloperoxidase assayMyeloperoxidase (MPO) was extracted from homogenized tissue by suspending the pellets in 0.5% hexadecyl trimethylammonium bromide in 50 mM phosphate buffer and MPO activity was assayed spectrophotometrically as described (29, 30).
DNA fragmentation detectionFor the detection of oligonucleosomes, a cell death detection ELISA plus kit (Boehringer, Mannheim, Germany) was used according to the manufacturer's instructions. For electrophoresis, DNA was extracted from cardiac tissue (LV apex) using a commercially available isolation kit (Genzyme TACS, R&D Systems, MN) (15). The DNA obtained was used in a ligation mediated polymerase chain reaction (LM-PCR) assay according to the manufacturer's instructions (Clontech Laboratories, Palo Alto, CA) (15).
Caspase-3 activity and Western blot analysis for procaspase-3
For measurements of caspase-3 activity, heart proteins were diluted and incubated at 25° C with the colorimetric substrate Ac-DEVD-pNA (Biomol, Plymouth, PA) in 96-well microtiter plates. Cleavage of the p-nitroaniline (p-NA) dye from the peptide substrate was determined by the measure of absorbance of p-NA at 405 nm in a microplate reader Digiscan (Asys Hitech, Cincinnati, OH) (14, 15). Results were calibrated with known concentrations of p-NA and expressed in picomoles of substrate cleaved per minute and per microgram proteins at 25° C.
For procaspase-3 immunoblotting, fresh heart tissue was resuspended in RIPA buffer. Lysates were centrifugated at 14,000 × g and 200 µg of supernatant was loaded on 12.5% polyacrylamide gels, electrophoresed, and transferred as previously described (14). Procaspase-3 was detected using a polyclonal rabbit anti-procaspase-3 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA), which recognizes the 32-kD unprocessed procaspase-3.
Isolation of mitochondria and swellingThe mitochondrial fraction was prepared as previoulsy described (31). For determination of swelling, mitochondria were washed and resuspended (1 mg/ml) in sucrose buffer. Mitochondrial swelling was estimated from the decrease in absorbance measured at 520 nm in a spectrophotometer as described (32). Large amplitude swelling was induced by addition of 320 µM calcium at the indicated time.
Western blot analysis for cytochrome c
Mitochondrial protein samples in loading buffer were run on 12% SDS-PAGE gels. The proteins on the gel were electrophoretically transferred to nitrocellulose membranes. After blocking, membranes were treated with mouse monoclonal anticytochrome c antibody (Pharmingen, Becton Dickinson Company). Membranes were then incubated with horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin G (IgG) secondary antibody (Sanofi Diagnostics Pasteur, Bio-Rad), washed, and bound antibodies were detected using chemiluminescence with an ECL Plus kit (Amersham).
Statistical Analysis
For in vitro and in vivo studies, we tested for differences using ANOVA procedures (SPSS 9.0 for Windows, IL). Data are presented as means ± SEM throughout. A value of p < 0.05 was considered significant.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Cyclosporin A Prevented Endotoxin-induced Myocardial Dysfunction
As shown in Table 1, left ventricle (LV) developed pressure (LVDP) and its first derivatives (i.e., dP/dtmax and dP/dtmin) were significantly decreased 4 h after administration of endotoxin as compared with control animals. Coinjection of CsA (10 mg/kg) largely prevented LV systolic function alterations of endotoxin-treated hearts (n = 7 in each group). FK 506 (3 mg/kg) had no detectable effects on myocardial function in endotoxin-treated animals (n = 7 in each group) (Table 1). Animals cotreated with endotoxin and CsA exhibited LVDP-preload relationships that were shifted upward compared with animals treated with endotoxin alone, suggesting improved systolic myocardial performance (Figure 1). Animals cotreated with endotoxin and FK 506 exhibited LVDP-preload relationships that were similar to animals treated with endotoxin alone (Figure 1). CsA and FK 506 treatment had no effects on myocardial function in control animals (Table 1).
|
|
5 to +20 mm Hg in order
to construct LV developed
pressure (LVDP)-preload relationship curves. Compared
with control, the LVDP-
preload relationships were
shifted downward (in the
direction of LV systolic performance decrease) in endotoxin-treated rats and in
endotoxin + FK 506-treated rats. Endotoxin + CsA-treated rat hearts exhibited a shift of LVDP-preload relationships upward compared with
endotoxin-treated rat hearts (in the direction of LV systolic performance increase). Endotoxin + FK 506-treated rat hearts exhibited
LVDP-preload relationships similar to endotoxin-treated rat hearts.
CsA and FK 506 had no effects on LV function in control rats (data not
shown). *p < 0.01 compared with control rats.
Cyclosporin A and Tacrolimus Reduced Endotoxin-induced Inflammation
CsA and FK 506 reduced serum TNF- levels in endotoxin-treated rats but had no effects on IL-1 and IL-6 levels (Figure 2A). Compared with control rats, heart MPO activity, an
index of heart leukocyte infiltration, was increased in endotoxin-treated rats. CsA and FK 506 reduced heart MPO activities
in endotoxin-treated rats (Figure 2B). Consistently, leukocyte
adhesion on the mesenteric venule, a surrogate of vascular inflammation, was increased in endotoxin-treated rats compared
with control rats. In endotoxin-treated rats, CsA and FK 506 administration provided significant reduction of adhesive interactions between leukocytes and venular endothelium (Table 2). Compared with endotoxin-treated rats, measured hemodynamic variables (i.e., mean arterial pressure and shear
rate) were unchanged (Table 2) in CsA and FK 506 endotoxin-treated rats, which suggest that these compounds did not interfere with the physical forces that modulate leukocyte behavior within the microvasculature.
|
p < 0.01 compared with endotoxin-treated rats). (B) Compared with control rats,
heart myeloperoxidase (MPO) activity, an index of heart leukocyte infiltration, increased in endotoxin-treated rats. CsA and FK 506 prevented heart MPO activities in endotoxin-treated rats. Results are displayed as mean ± SEM. (*p < 0.01 compared with control rats; n = 5 in each group;
|
Cyclosporin A Prevented Endotoxin-induced Myocardial Cell Nuclear Apoptosis
As shown in Figure 3A, significant nuclear DNA fragmentation detected by agarose gel electrophoresis was evident 4 h after endotoxin injection in the myocardium. Oligonucleosomal DNA fragmentation confirmed nuclear apoptosis 4 h after endotoxin injection (Figures 3A and 3B). CsA protected myocardial cells from DNA fragmentation induced by endotoxin, whereas FK 506 had no effects (Figure 3).
|
Effects of Cyclosporin A and Tacrolimus on Endotoxin-induced Caspase-3 Activation
Four hours after endotoxin administration, caspase-3 activity assessed by measuring hydrolysis of the preferential substrate Ac-DEVD-pNA, increased in rat heart (n = 8 rats in each group) (Figure 4A). Results of immunoblotting (n = 4 in each group) indicated that in contrast to control hearts, the proteolytic activation of procaspase-3 was significant in endotoxin-treated myocardium (Figure 4B). Neither CsA nor FK 506 prevented proteolytic activation of procaspase-3 and caspase-3 activity increases in endotoxin-treated rat hearts.
|
Cyclosporin A Prevented Mitochondrial Cytochrome c Release in the Septic Heart
Results of immunoblotting indicated that cytochrome c, in contrast to normal hearts, was substantially reduced in the mitochondrial fraction of endotoxin-treated rat hearts (Figure 5). The reduction in mitochondrial cytochrome c observed in endotoxin-treated rats was prevented by CsA, but not by FK 506 (Figure 5).
|
In Vitro Effects of Cyclosporin A and Tacrolimus on Heart Mitochondria Isolated from Control and Endotoxin-treated Rats
In these experiments, we have tested the capacity of CsA to inhibit mitochondria permeability transition (MPT) in our model of sepsis. Heart mitochondria were purified from control (Figure 6A) and endotoxin-treated rats (Figure 6B). Then, MPT was determined as large amplitude swelling after addition of a high dose of calcium, a standard protocol for the induction of permeability transition. As shown in Figure 5, no difference could be detected in the MPT-dependent colloidosmotic swelling induced by calcium of isolated mitochondria from control (Figure 5A) and endotoxin-treated rats (Figure 5B). As expected, preincubation of mitochondria with CsA fully inhibited calcium-induced PT (Figure 6). The MPT inhibitory effect of CsA was observed to the same extent on mitochondria from control and also on mitochondria from endotoxin-treated rats. In contrast, FK 506 was unable to protect mitochondria from MPT (Figure 6) even at high concentrations (data not shown).
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
In this rat model of endotoxin-induced myocardial dysfunction,
we found evidence of inflammation and end-stage apoptosis that may involve downstream caspase activation and mitochondria-related pathway events such as cytochrome c release. Pharmacological manipulation with immunosuppressors reduced endotoxin-induced inflammation and myocardial apoptosis. Both
CsA and FK 506 reduced serum TNF- levels, heart leukocyte
sequestration, and venular endothelial adhesion in endotoxemic rats. CsA, but not FK 506, was able to offer protection
from endotoxin-induced myocardial dysfunction and apoptosis. We speculated that the differential effects of the calcineurin inhibitors on myocardial dysfunction may be related to the unique effects of CsA on the mitochondrial function.
Proinflammatory mediators and leukocytes activated by
proinflammatory cytokines contribute to the development of
cardiovascular dysfunction associated with endotoxemia (2, 4,
7, 11, 12). The relevance of cytokine release and leukocyte
adhesion in mediating cardiovascular dysfunction is illustrated
by the finding that reduction of circulating cytokines and
leukocyte activation attenuates endotoxin-induced cardiovascular dysfunction in shock models (33). In our model, endotoxin induced increases in TNF- serum levels, heart MPO,
and mesenteric endothelial-leukocyte interactions, which were
mainly prevented by the administration of calcineurin inhibitors
CsA and FK 506. These results are consistent with the finding
that CsA and FK 506 modulate cytokine and adhesion molecule gene expression (36, 37) and attenuate cardiovascular failure by interfering with the processes of leukocyte adhesion and
proinflammatory cytokine production in experimental models (37, 38).
Indeed, the identification of calcineurin as a target for the
immunosuppressive drugs cyclosporin and FK 506 suggests a
critical role for this phosphatase in the regulation of T cell reactivity and cytokine gene expression (22, 23). Cyclosporin
and FK 506 inhibit calcineurin catalytic activity through complexes with cyclophilins and FKBP12, respectively. The mechanism whereby calcineurin promotes T-cell activation and cytokine activation has been largely attributed to the family of
transcriptional regulators referred to as nuclear factor of activated T cells (NFAT). Dephosphorylation of NFAT and its
translocation to the nucleus are followed by induction of several cytokines, including IL-2, IL-4, and TNF- (39). Whereas
NFAT factors are important downstream effectors, calcineurin also regulates activity of the transcriptional regulatory factors nuclear-
B, Elk-1, and myocyte enhancer factor-2 (39, 40). In
addition, recent findings suggest that calcineurin promotes nitric oxide synthase, c-jun N-terminal kinase, extracellular signal-regulated kinase, and protein kinase C and 
activation (40). Overall, these findings suggest a critical role for calcineurin in the regulation of several gene expressions (22, 23,
40) involved in the adaptative myocardial response to stress.
Hence, inhibition of calcineurin activity may reduce endotoxin-induced cardiovascular inflammation and myocardial
dysfunction. However, in our model of sepsis, CsA, but not
FK 506, prevented myocardial dysfunction, suggesting that cyclosporin could improve myocardial function by interfering
with different pathways. Indeed, in addition to their immunosuppressive effects, calcineurin inhibitors regulate processes
of cellular apoptosis, suggesting that calcineurin is critical in
death signaling (21, 41).
In the heart, apoptosis has been implicated as a major process in diseases including dilated cardiomyopathy, myocarditis, and ischemic reperfusion injury (42, 43). In cardiomyocytes, apoptosis pathways can also be activated under conditions such as cytokine and endotoxin stimulation, in vitro (13). Recently, we (14, 15) and other groups (16) have shown that in vivo, endotoxin induces myocardial apoptosis. In these studies, however, the observed small extent of cardiomyocyte nuclear apoptosis was likely insufficient to directly account for myocardial dysfunction. Therefore, it has been suggested that apoptotic pathways may be linked to myocardial dysfunction in other ways, involving multiple caspase activation and altered mitochondrial signaling. In the present study, we confirmed that endotoxin induces heart nuclear apoptosis as evidenced by detection of oligonucleosomes and electrophoresis DNA laddering (44). Consistent with previous results (13, 14, 16), we documented activation of apoptotic pathways in endotoxin-treated heart by measuring cytosolic activation of downstream caspase-3 and mitochondria cytochrome c release.
Growing evidence suggests that calcineurin participates in
pathways of apoptotic death. Calcineurin inhibitors regulate
apoptosis in cells stimulated by TNF- and nitric oxide (23,
45). For example, cyclosporin and FK 506 potently inhibit cytotoxicity induced by TNF- in rat hepatoma cells. Cyclosporin
and FK 506 may oppose programmed cell death by inhibiting
calcineurin activity, downstream caspase activaty, and mitochondrial signaling such as the mitochondrial pore transition
and expression of Bcl-2. Consistently, in endotoxin-treated
heart, CsA reduced heart internucleosomal DNA fragmentation. We found that neither cyclosporin nor FK 506 prevented
increases in downstream caspase-3 activity, which was assessed by procaspase-3 protein level and DEVDase activity.
However, cyclosporin, but not FK 506, prevented mitochondrial cytochrome c release in vivo and mitochondrial pore
transition in vitro. These results suggest that in our model, cyclosporin may oppose cell death by inhibiting mitochondrial
signaling (23, 41).
The differential effects of CsA and FK 506 on myocardial dysfunction could be related to their known opposite effects on mitochondrial permeability transition and cytochrome c release (21, 41). The mitochondrial permeability transition is caused by the opening of a nonspecific pore in the inner mitochondrial membrane under conditions of mitochondrial calcium overload, oxidative stress, and adenine nucleotide depletion (21, 32). CsA, but not FK 506, prevents in vitro mitochondrial permeability transition and cytochrome c release by blocking translocation of the matrix-specific cyclosporin D to the inner membrane of the mitochondria, thereby decreasing the mitochondrial megachannel sensibility to succinate and calcium ions and reducing mitochondrial swelling (21, 22). Indeed, we confirmed that CsA, as opposed to FK 506, prevented mitochondrial cytochrome c release in vivo in septic hearts and mitochondrial swelling in energized isolated mitochondria from control and septic hearts in vitro. However, in endotoxemic rats, CsA and FK 506 in vivo treatment effects on mitochondrial swelling were not tested because no differences between control and septic energized mitochondria were observed in our experimental setting. Overall, our results are consistent with previous studies showing that analogues of CsA inhibit the permeability transition pore and are able to provide myocardial protection (22, 24). Indeed, CsA provide protective effects in reoxygenated cardiac myocytes and reperfused heart (22, 24). The mechanisms of cyclosporin-induced myocardial protection remain speculative. It could be hypothetized, however, that beneficial effects of CsA on endotoxin-induced dysfunction may be related to independent mitochondria permeability transition effects (46), such as regulatory roles of immunophilins at the ryanodine receptor and antiapoptotic gene product bcl-2 (23, 39) and changes in nitric oxide production (50, 51).
In conclusion, these observations strongly suggest that (1) mitochondrial cytochrome c release may play an important role in the onset of end-stage nuclear apoptosis in endotoxemic heart and (2) CsA, which blocks cytochrome c release, was able to reduce endotoxin-induced heart end-stage nuclear apoptosis and myocardial dysfunction, which was not observed with FK 506. The precise mechanisms of the beneficial effects of cyclosporin warrant further investigations.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Dr. Rémi Nevière, M.D., Ph.D., Département de Physiologie, Faculté de Médecine, 1, place de Verdun, Lille Cedex 59045, France. E-mail: rneviere{at}univ-lille2.fr
(Received in original form May 17, 2001 and accepted in revised form November 26, 2001).
This article has an online data supplement, which is accessible from this issue's table of contents online at www.atsjournals.orgAcknowledgments: This work was supported by IFR22, INSERM, Université de Lille 2, and by grants from MENRT and INSERM: Biologie et pathologie des régulations cellulaires. U459 and EA 2689 belong to IFR 22 (CHU, COL, INSERM, IRCL, Université Lille 2).
| |
References |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-1553 .
2.
Natanson C,
Eichenholz PW,
Danner RL,
Eichacker PQ,
Hoffman WD,
Kuo GC.
Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.
J Exp Med
1989;
169:
823-832
3.
Parker MM,
McCarthy KE,
Ognibene FP,
Parrillo JE.
Right ventricular
dysfunction and dilatation, similar to left ventricular changes, characterize
the cardiac depression of septic shock in humans.
Chest
1990;
97:
126-131
4. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998; 6: 181-193 [Medline].
5. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287 [Abstract].
6. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96: 1042-1052 .
7. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 1996; 28: 1631-1639 [Medline].
8.
Meldrum DR.
Tumor necrosis factor in the heart.
Am J Physiol
1998;
274:
R577-R595
9.
Finkel MS,
Oddis CV,
Jacob TD,
Watkins SC,
Hattler BG,
Simmons RL.
Negative inotropic effects of cytokines on the heart mediated by
nitric oxide.
Science
1992;
257:
387-389
10. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med 1999; 27: 1775-1780 [Medline].
11.
Goddard CM,
Allard MF,
Hogg JC,
Walley KR.
Myocardial morphometric changes related to decreased contractility after endotoxin.
Am
J Physiol
1996;
270:
H1446-H1452
12.
Goddard CM,
Allard MF,
Hogg JC,
Herbertson MJ,
Walley KR.
Prolonged leukocyte transit time in coronary microcirculation of endotoxemic pigs.
Am J Physiol
1995;
269:
H1389-H1397
13. Comstock KL, Krown KA, Page MT, Martin D, Ho P, Pedraza M. LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 1998; 30: 2761-2775 [Medline].
14.
Fauvel H,
Marchetti P,
Chopin C,
Formstecher P,
Neviere R.
Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis.
Am J Physiol Heart Circ Physiol
2001;
280:
H1608-H1614
15.
Neviere R,
Fauvel H,
Chopin C,
Formstecher P,
Marchetti P.
Caspase
inhibition prevents cardiac dysfunction and heart apoptosis in a rat
model of sepsis.
Am J Respir Crit Care Med
2001;
163:
218-225
16.
McDonald TE,
Grinman MN,
Carthy CM,
Walley KR.
Endotoxin infusion in rats induces apoptotic and survival pathways in hearts.
Am J
Physiol
2000;
279:
H2053-H2061
17.
Thornberry NA,
Lazebnik Y.
Caspases: enemies within.
Science
1998;
281:
1312-1316
18. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-698 [Medline].
19.
Narula J,
Pandey P,
Arbustini E,
Haider N,
Narula N,
Kolodgie FD.
Apoptosis in heart failure: release of cytochrome c from mitochondria
and activation of caspase-3 in human cardiomyopathy.
Proc Natl Acad
Sci USA
1999;
96:
8144-8149
20. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 1998; 8: 267-271 . [Medline]
21. Halestrap AP, Kerr PM, Javadov S, Woodfield KY. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1998; 1366: 79-94 [Medline].
22. Halestrap AP, Connern CP, Griffiths EJ, Kerr PM. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem 1997; 174: 167-172 [Medline].
23. Hortelano S, Lopez-Collazo E, Bosca L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999; 126: 1139-1146 [Medline].
24. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993; 25: 1461-1469 [Medline].
25. Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem J 1991; 274: 611-614 .
26.
Neviere RR,
Cepinskas G,
Madorin WS,
Hoque N,
Karmazyn M,
Sibbald WJ.
LPS pretreatment ameliorates peritonitis-induced myocardial inflammation and dysfunction: role of myocytes.
Am J Physiol
1999;
277:
H885-H892
27.
Neviere R,
Guery B,
Mordon S,
Zerimech F,
Charre S,
Wattel F.
Inhaled
NO reduces leukocyte-endothelial cell interactions and myocardial
dysfunction in endotoxemic rats.
Am J Physiol
2000;
278:
H1783-H1790
28. Fox-Robichaud A, Payne D, Hasan SU, Ostrovsky L, Fairhead T, Reinhardt P. Inhaled NO as a viable antiadhesive therapy for ischemia/ reperfusion injury of distal microvascular beds. J Clin Invest 1998; 101: 2497-2505 [Medline].
29. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-209 [Medline].
30. Griswold DE, Hillegass LM, Hill DE, Egan JW, Smith EF III.. Method for quantification of myocardial infarction and inflammatory cell infiltration in rat cardiac tissue. J Pharmacol Methods 1988; 20: 225-235 [Medline].
31. Petit PX, Goubern M, Diolez P, Susin SA, Zamzami N, Kroemer G. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition. FEBS Lett 1998; 426: 111-116 [Medline].
32.
Marchetti P,
Susin SA,
Decaudin D,
Gamen S,
Castedo M,
Hirsch T.
Apoptosis-associated derangement of mitochondrial function in cells
lacking mitochondrial DNA.
Cancer Res
1996;
56:
2033-2038
33. Walsh CJ, Carey PD, Cook DJ, Bechard DE, Fowler AA, Sugerman HJ. Anti-CD18 antibody attenuates neutropenia and alveolar capillary-membrane injury during gram-negative sepsis. Surgery 1991; 110: 205-211 [Medline].
34.
Jaeschke H,
Farhood A,
Smith CW.
Neutrophil-induced liver cell injury
in endotoxin shock is a CD11b/CD18-dependent mechanism.
Am J
Physiol
1991;
261:
G1051-G1056
35.
Thomas JR,
Harlan JM,
Rice CL,
Winn RK.
Role of leukocyte CD11/
CD18 complex in endotoxic and septic shock in rabbits.
J Appl Physiol
1992;
73:
1510-1516
36. Charreau B, Coupel S, Goret F, Pourcel C, Soulillou JP. Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation. Transplantation 2000; 69: 945-953 [Medline].
37. Squadrito F, Altavilla D, Squadrito G, Saitta A, Campo GM, Arlotta M. Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Eur J Pharmacol 1999; 364: 159-168 [Medline].
38. Kubes P, Hunter J, Granger DN. Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat. Dig Dis Sci 1991; 36: 1469-1472 [Medline].
39.
Molkentin JD.
Calcineurin and beyond: cardiac hypertrophic signaling.
Circ Res
2000;
87:
731-738
40.
Olson EN,
Molkentin JD.
Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?
Circ Res
1999;
84:
623-632
41.
Friberg H,
Ferrand-Drake M,
Bengtsson F,
Halestrap AP,
Wieloch T.
Cyclosporin A, but not FK 506, protects mitochondria and neurons
against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death.
J Neurosci
1998;
18:
5151-5159
42.
Haunstetter A,
Izumo S.
Apoptosis: basic mechanisms and implications
for cardiovascular disease.
Circ Res
1998;
82:
1111-1129
43.
Davies MJ.
Apoptosis in cardiovascular disease.
Heart
1997;
77:
498-501
.
44. Scarabelli TM, Knight RA, Rayment NB, Cooper TJ, Stephanou A, Brar BK. Quantitative assessment of cardiac myocyte apoptosis in tissue sections using the fluorescence-based tunel technique enhanced with counterstains. J Immunol Methods 1999; 228: 23-28 [Medline].
45. Kantrow SP, Gierman JL, Jaligam VR, Zhang P, Piantadosi CA, Summer WR, Lancaster JR. Regulation of tumor necrosis factor cytotoxicity by calcineurin. FEBS Lett 2000; 483: 119-124 [Medline].
46. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 1998; 98: 1355-1357 [Medline].
47. Nazareth W, Yafei N, Crompton M. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol 1991; 23: 1351-1354 [Medline].
48.
De Windt LJ,
Lim HW,
Taigen T,
Wencker D,
Condorelli G,
Dorn GW.
Calcineurin-mediated hypertrophy protects cardiomyocytes from apo-
ptosis in vitro and in vivo: an apoptosis-independent model of dilated
heart failure.
Circ Res
2000;
86:
255-263
49.
Sussman MA,
Lim HW,
Gude N,
Taigen T,
Olson EN,
Robbins J.
Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Science
1998;
281:
1690-1693
50.
duBell WH,
Gaa ST,
Lederer WJ,
Rogers TB.
Independent inhibition of
calcineurin and K+ currents by the immunosuppressant FK-506 in rat
ventricle.
Am J Physiol
1998;
275:
H2041-H2052
51.
Massoudy P,
Zahler S,
Kupatt C,
Reder E,
Becker BF,
Gerlach E.
Cardioprotection by cyclosporine A in experimental ischemia and reperfusion
evidence for a nitric oxide-dependent mechanism mediated
by endothelin.
J Mol Cell Cardiol
1997;
29:
535-544
[Medline].
This article has been cited by other articles:
 |
|
 |
|
  J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes J. Am. Coll. Cardiol., January 30, 2007; 49(4): 491 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Larche, S. Lancel, S. M. Hassoun, R. Favory, B. Decoster, P. Marchetti, C. Chopin, and R. Neviere Inhibition of Mitochondrial Permeability Transition Prevents Sepsis-Induced Myocardial Dysfunction and Mortality J. Am. Coll. Cardiol., July 18, 2006; 48(2): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Joshi, M. W. Julian, J. E. Huff, J. A. Bauer, Y. Xia, and E. D. Crouser Calcineurin Regulates Myocardial Function during Acute Endotoxemia Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 999 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lancel, O. Joulin, R. Favory, J. F. Goossens, J. Kluza, C. Chopin, P. Formstecher, P. Marchetti, and R. Neviere Ventricular Myocyte Caspases Are Directly Responsible for Endotoxin-Induced Cardiac Dysfunction Circulation, May 24, 2005; 111(20): 2596 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nathan, I. Friehs, Y.-H. Choi, D. B. Cowan, H. Cao-Danh, F. X. McGowan, and P. J. del Nido Cyclosporin A But Not FK-506 Protects Against Dopamine-Induced Apoptosis in the Stunned Heart Ann. Thorac. Surg., May 1, 2005; 79(5): 1620 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. Davani, D. R. Dorscheid, C.-H. Lee, C. van Breemen, and K. R. Walley Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1013 - H1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Tobin Critical Care Medicine in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 294 - 305. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |